Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).

Official Title

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Keywords

Non-small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC), Cancer, Telisotuzumab vedotin, ABBV-399, c-Met, c-Met overexpression, metastatic, MET gene amplification, LUMINOSITY, Lung Neoplasms, Non-Small-Cell Lung Carcinoma

Eligibility

Locations

  • University of California, Los Angeles /ID# 203219
    Los Angeles California 90095 United States
  • LA Hematology-Oncology Med Group /ID# 203338
    Orange California 92868 United States
  • Sutter Medical Center Sacramen /ID# 203299
    Sacramento California 95816 United States
  • Icri /Id# 227835
    Whittier California 90603 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT03539536
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 270 people participating
Last Updated